SHL Medical

SHL Medical is a privately held, revenue-generating contract development and manufacturing organization (CDMO) specializing in advanced drug delivery devices. With over 6,000 employees, the company has established itself as a market leader in autoinjectors, offering full-service solutions from concept to commercial manufacturing. Its core value proposition lies in enabling patient self-administration for chronic conditions, thereby improving adherence and reducing healthcare system costs. SHL leverages deep engineering expertise and strategic global manufacturing locations to serve leading pharmaceutical partners worldwide.

Design, development, and manufacturing platform for advanced drug delivery devices, including electromechanical/mechanical autoinjectors (Molly, Maggie platforms), pen injectors, and next-gen connected delivery systems (Elexy platform).

SHL competes in a crowded field of drug delivery device companies and CDMOs, including major players like West Pharmaceutical Services, Gerresheimer, Ypsomed, and Bespak. Its differentiation lies in its deep end-to-end service model, specific autoinjector platform expertise, and focus on strategic alliance partnerships rather than transactional supply.